Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey

GPR40 (FFAR1) is a promising target for the managing type 2 diabetes (T2D). The most advanced GPR40 agonist TAK-875 exhibited satisfactory glucose-lowering effects in phase II and III studies. However, the phase III studies of TAK-875 revealed drug-induced liver injury (DILI). It is unknown whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Bazydlo-Guzenda, Katarzyna, Buda, Pawel, Mach, Mateusz, Pieczykolan, Jerzy, Kozlowska, Izabela, Janiszewski, Michal, Drzazga, Ewa, Dominowski, Jakub, Ziolkowski, Hubert, Wieczorek, Maciej, Gad, Shayne Cox
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459971/
https://www.ncbi.nlm.nih.gov/pubmed/34555055
http://dx.doi.org/10.1371/journal.pone.0257477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459971/
https://www.ncbi.nlm.nih.gov/pubmed/34555055
http://dx.doi.org/10.1371/journal.pone.0257477

Ejemplares similares